Triamcinolone acetonide combined with aminoguanidine inhibits inflammation and oxidative stress, improves vascular endothelial and retinal function and reduces VEGF expression in diabetic retinopathy patients

Xu,Kai; Qian,Hanliang; Zou,Meibo

doi:10.3892/etm.2020.8478

Triamcinolone acetonide combined with aminoguanidine inhibits inflammation and oxidative stress, improves vascular endothelial and retinal function and reduces VEGF expression in diabetic retinopathy patients

Authors:
- Kai Xu
- Hanliang Qian
- Meibo Zou
View Affiliations

Affiliations: Department of Ophthalmology, Taizhou Second People's Hospital Affiliated to Yangzhou University, Taizhou, Zhejiang 225500, P.R. China, Department of Ophthalmology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China, Department of Ophthalmology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, P.R. China
Published online on: January 30, 2020 https://doi.org/10.3892/etm.2020.8478
Pages: 2519-2526
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Effects of triamcinolone acetonide (TA) combined with aminoguanidine (AG) on vascular endothelial function, vascular endothelial growth factor (VEGF) expression and retinal function in diabetic retinopathy (DR) patients were studied. A total of 100 patients with DR admitted to the Taizhou Second People's Hospital Affiliated to Yangzhou University from January 2016 to December 2018 were collected and randomly divided into observation group (n=50) and control group (n=50). The control group was only treated with TA (4 mg), while the observation group was additionally treated with AG (50 mg/kg). The therapeutic effect and adverse reactions were observed, and the changes in blood glucose (GLU), blood lipid, serum inflammatory cytokines and oxidative stress indexes before and after treatment were detected. Moreover, the serum VEGF level was examined, the central macular thickness (CMT), retinal neovascularization (RNV) leakage area and best corrected visual acuity (BCVA) of retinopathy were observed, and the vascular endothelial function indexes such as nitric oxide (NO), endothelin‑1 (ET‑1) and intercellular adhesion molecule‑1 (ICAM‑1) were detected. The therapeutic effect in the observation group was significantly better than that in control group (P<0.05). In observation group after treatment, the levels of GLU, total cholesterol (TC), triglyceride (TG), interleukin‑6 (IL‑6), tumor necrosis factor‑α (TNF‑α), myeloperoxidase (MPO), malondialdehyde (MDA) and catalase (CAT) in the serum, VEGF, CMT and RNV, as well as NO, ET‑1 and ICAM‑1 were remarkably decreased (P<0.05), while those of superoxide dismutase (SOD) and BCVA were evidently increased (P<0.05). The changes were more significant at 3 months after treatment than those at 1 month. TA combined with AG can inhibit inflammation and oxidative stress, improve vascular endothelial function and retinal function and reduce VEGF expression in DR patients. The overall effect of the combined therapy is good, and its application is worth popularizing.

View Figures

View References

1	Zhang HY, Ruan LB, Li Y, Yang TR, Liu WJ, Jiang YX, Li TR, Quan J and Xuan W: ICOS/ICOSL upregulation mediates inflammatory response and endothelial dysfunction in type 2 diabetes mellitus. Eur Rev Med Pharmacol Sci. 22:8898–8908. 2018.PubMed/NCBI View Article : Google Scholar
2	Sharma S, Oliver-Fernandez A, Liu W, Buchholz P and Walt J: The impact of diabetic retinopathy on health-related quality of life. Curr Opin Ophthalmol. 16:155–159. 2005.PubMed/NCBI View Article : Google Scholar
3	Zheng Y, He M and Congdon N: The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 60:428–431. 2012.PubMed/NCBI View Article : Google Scholar
4	Fletcher EL, Phipps JA, Ward MM, Puthussery T and Wilkinson-Berka JL: Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr Pharm Des. 13:2699–2712. 2007.PubMed/NCBI View Article : Google Scholar
5	Barber AJ: A new view of diabetic retinopathy: A neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry. 27:283–290. 2003.PubMed/NCBI View Article : Google Scholar
6	Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS, Kester M, Kimball SR, Krady JK, LaNoue KF, et al: JDRF Diabetic Retinopathy Center Group: Diabetic retinopathy: Seeing beyond glucose-induced microvascular disease. Diabetes. 55:2401–2411. 2006.PubMed/NCBI View Article : Google Scholar
7	Lieth E, Gardner TW, Barber AJ and Antonetti DA: Penn State Retina Research Group: Retinal neurodegeneration: Early pathology in diabetes. Clin Exp Ophthalmol. 28:3–8. 2000.PubMed/NCBI View Article : Google Scholar
8	Pemp B, Garhofer G, Weigert G, Karl K, Resch H, Wolzt M and Schmetterer L: Reduced retinal vessel response to flicker stimulation but not to exogenous nitric oxide in type 1 diabetes. Invest Ophthalmol Vis Sci. 50:4029–4032. 2009.PubMed/NCBI View Article : Google Scholar
9	Luo D, Fan Y and Xu X: The effects of aminoguanidine on retinopathy in STZ-induced diabetic rats. Bioorg Med Chem Lett. 22:4386–4390. 2012.PubMed/NCBI View Article : Google Scholar
10	Mahmood D, Singh BK and Akhtar M: Diabetic neuropathy: Therapies on the horizon. J Pharm Pharmacol. 61:1137–1145. 2009.PubMed/NCBI View Article : Google Scholar
11	Joussen AM, Doehmen S, Le ML Koizumi K, Radetzky S, Krohne TU, Poulaki V, Semkova I and Kociok N: TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol Vis. 15:1418–1428. 2009.PubMed/NCBI
12	Noor JI, Ikeda T, Mishima K, Aoo N, Ohta S, Egashira N, Iwasaki K, Fujiwara M and Ikenoue T: Short-term administration of a new free radical scavenger, edaravone, is more effective than its long-term administration for the treatment of neonatal hypoxic-ischemic encephalopathy. Stroke. 36:2468–2474. 2005.PubMed/NCBI View Article : Google Scholar
13	Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K, Foiles PG, Freedman BI, Raskin P, Ratner RE, et al: ACTION I Investigator Group: Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol. 24:32–40. 2004.PubMed/NCBI View Article : Google Scholar
14	Eldred WD and Blute TA: Imaging of nitric oxide in the retina. Vision Res. 45:3469–3486. 2005.PubMed/NCBI View Article : Google Scholar
15	Jonas JB, Kreissig I, Söfker A and Degenring RF: Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 121:57–61. 2003.PubMed/NCBI View Article : Google Scholar
16	Jakus V and Rietbrock N: Advanced glycation end-products and the progress of diabetic vascular complications. Physiol Res. 53:131–142. 2004.PubMed/NCBI
17	Qazi Y, Maddula S and Ambati BK: Mediators of ocular angiogenesis. J Genet. 88:495–515. 2009.PubMed/NCBI View Article : Google Scholar
18	Li ZP, Xu X, Huang YF, Zhu JF, Wang XJ, Hu HH and He ZP: Exogenous advanced glycosylation end products induce diabetes-like vascular dysfunction in normal rats: A factor for occurrence of diabetic retinopathy. Zhonghua Yan Ke Za Zhi. 39:352–356. 2003.(In Chinese). PubMed/NCBI
19	Yin Y, Chen F, Wang W, Wang H and Zhang X: Resolvin D1 inhibits inflammatory response in STZ-induced diabetic retinopathy rats: Possible involvement of NLRP3 inflammasome and NF-κB signaling pathway. Mol Vis. 23:242–250. 2017.PubMed/NCBI
20	Mishra A and Newman EA: Aminoguanidine reverses the loss of functional hyperemia in a rat model of diabetic retinopathy. Front Neuroenergetics. 3(10)2012.PubMed/NCBI View Article : Google Scholar
21	Sun W, Yu WY, Yu DJ, Zhao TL, Wu LJ and Han WY: The effects of recombinant human growth hormone (rHGH) on survival of slender narrow pedicle flap and expressions of vascular endothelial growth factor (VEGF) and classification determinant 34 (CD34). Eur Rev Med Pharmacol Sci. 22:771–777. 2018.PubMed/NCBI View Article : Google Scholar
22	Lenz T, Haak T, Malek J, Gröne HJ, Geiger H and Gossmann J: Vascular endothelial growth factor in diabetic nephropathy. Kidney Blood Press Res. 26:338–343. 2003.PubMed/NCBI View Article : Google Scholar
23	Mehta H, Gillies MC and Fraser-Bell S: Combination of vascular endothelial growth factor inhibitors and laser therapy for diabetic macular oedema: A review. Clin Exp Ophthalmol. 44:335–339. 2016.PubMed/NCBI View Article : Google Scholar
24	Riches K, Franklin L, Maqbool A, Peckham M, Adams M, Bond J, Warburton P, Feric NT, Koschinsky ML, O'Regan DJ, et al: Apolipoprotein(a) acts as a chemorepellent to human vascular smooth muscle cells via integrin αVβ3 and RhoA/ROCK- mediated mechanisms. Int J Biochem Cell Biol. 45:1776–1783. 2013.PubMed/NCBI View Article : Google Scholar
25	Arden GB and Sivaprasad S: The pathogenesis of early retinal changes of diabetic retinopathy. Doc Ophthalmol. 124:15–26. 2012.PubMed/NCBI View Article : Google Scholar
26	Giove TJ, Deshpande MM, Gagen CS and Eldred WD: Increased neuronal nitric oxide synthase activity in retinal neurons in early diabetic retinopathy. Mol Vis. 15:2249–2258. 2009.PubMed/NCBI